Search

Introduction: Our understanding of how fine particulate matter (PM 2.5 ) impacts cognitive functioning is limited. Systemic inflammation processes may play a role in mediating this effect., Methods: This prospective cohort study used data from 66,254 participants aged 18+ between 2006 and 2015 from the Dutch Lifelines Cohort Study and Biobank. Causal mediation analysis was conducted to examine the impact of ambient PM 2.5 exposure on cognitive processing time (CPT), using the change in white blood cell (WBC) count and its subtypes as potential mediators., Results: Heightened PM 2.5 exposure was associated with slower CPT (total effect = 81.76 × 10 -3 , 95% confidence interval [CI] 59.51 × 10 -3 -105.31 × 10 -3 ). The effect was partially mediated via increased WBC count (indirect effect [IE] = 0.42 × 10 -3 , 95% CI 0.07 × 10 -3 -0.90 × 10 -3 ), particularly driven by an increase in monocytes (IE = 0.73 × 10 -3 , 95% CI 0.24 × 10 -3 -1.31 × 10 -3 )., Discussion: Systemic inflammation processes may partially explain the harmful effects of PM 2.5 on cognitive functioning, why lower levels of systemic inflammation may help contain its neurotoxic effects., Highlights: The pathways leading to the neurotoxic effects of fine particulate matter (PM 2.5 ) are poorly understood. We analyzed data from over 66,000 participants using causal pathway analysis. Increased white blood cell (WBC) count mediates the effect of PM 2.5 on cognitive functioning. Monocyte count played a crucial role in this low-pollution setting. Systemic inflammation may contribute to the neurotoxic effects of PM 2.5 ., (© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)

Introduction: Previous studies showed associations of brain volume differences and biomarker evidence for Alzheimer's disease (AD) in subjective cognitive decline (SCD). The consistency of this finding across SCD studies has not been investigated., Methods: We studied gray matter volume differences between SCD subjects with and without cerebrospinal fluid biomarker evidence for AD across three European memory clinic samples (German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia study, Amsterdam, Barcelona). Analysis of covariance models with samples and cerebrospinal fluid biomarkers as between-subject factors were calculated., Results: A significant main effect for AD biomarker (Aβ 42 - > Aβ 42 +) in the left medial temporal lobe (MTL) was found, with the absence of main effects for sample or interaction effects between AD biomarker and sample. This indicates consistent lower left MTL volume across three samples in SCD subjects with abnormal Aβ 42 levels., Discussion: Our results support the model that in the presence of AD pathology, SCD corresponds to the late preclinical stage (stage 2 of AD) with smaller MTL volumes., (Copyright © 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.)